Previous 10 | Next 10 |
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023 Disclosed cash of approximately $13 million as of December 31, 2022, non-inclusive of the February 2023 public offering Increased cash positio...
2023-03-15 13:51:56 ET The following slide deck was published by Avalo Therapeutics, Inc. in conjunction with this event. For further details see: Avalo Therapeutics (AVTX) Investor Presentation - Slideshow
WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at Oppenheimer's 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 1:20 p....
Strategic partnership will produce FDCA from Origin’s carbon-negative platform for producing chemical intermediates from sustainable wood residues and Avantium’s YXY ® Technology Origin Materials, Inc. (“Origin” and “Origin Materials”...
Avalo Therapeutics ( NASDAQ: AVTX ) shares dropped 12% Friday morning after the biotechnology company priced its $15M securities offering . The offering comprises 3.77M shares of common stock and warrants to purchase up to 3.77M shares, issued at a price to the public of $3.98...
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of its common stock and warrants to purchase up to an aggregate of 3,770,000 shares of common st...
Shares of Avalo Therapeutics ( NASDAQ: AVTX ) -20.4% after the bell on Thursday after the company said it commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase common shares. All of the shares and warrants in the proposed ...
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. Al...
Topline data expected in the second quarter of 2023 WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed enrollment of the 80 patients targeted for the Phase 2 PEAK Trial evaluating AVTX-002 (anti-LIGHT...
Avalo Therapeutics press release ( NASDAQ: AVTX ): Q3 GAAP EPS of $0.34 beats by $1.04 . Revenue of $14.95M (+1007.4% Y/Y). Avalo had $16.9 million in cash as of September 30, 2022, representing a $37.7 million decrease compared to December 31, 2021. For furt...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...